The Special Committee of State Attorneys General are now soliciting grant applications from academic institutions, nonprofit organizations with current 501(c)(3) status with expertise and experience in health-related or consumer protection issues, government agencies, and collaborations of any of the above for grants to promote evidence based prescribing nationwide.
The Special Committee anticipates that it will make up to six grants, ranging from $500,000 to $12,000,000.
The deadline for physically submitting Grant Applications is 5:00 PM, Thursday, May 6,
2010. The Request for Grant Applications and the Appendices A-E Application for Funding Forms are available at: http://www.cypresfunds.net/neurontin.html
Showing posts with label neurontin. Show all posts
Showing posts with label neurontin. Show all posts
Friday, February 05, 2010
Wednesday, October 08, 2008
Pfizer - Neurontin: file under "dirty tricks"
Anyone know more about the people named in red?
Pfizer tried to suppress medical studies that reached unfavorable conclusions about the effectiveness of the company's epilepsy drug Neurontin, internal Pfizer documents submitted in a lawsuit against the company showed.
The documents suggest that Pfizer's marketers influenced Neurontin's scientific record to boost sales at least until 2003 by delaying the publication or altering the conclusions of studies that had found no evidence the drug worked for various conditions besides epilepsy.
The documents, including reports by experts who reviewed thousands of company documents for plaintiffs, were submitted to the U.S. District Court in Boston.
In the case of the European study, called 224, the full findings were never published as a stand-alone paper; data from the study were pooled into results from several other Pfizer studies and published in a minor journal in 2003.
"We must delay publication of 224, as its results were not positive," wrote Pfizer marketing executive John Marino in a September 2000 e-mail to Angela Crespo, senior manager of major markets for Neurontin.
Later that month, Michael Rowbotham, Neurontin team leader, e-mailed Crespo about the problem of Dr. John Reckless, an investigator on the study who was pressing Pfizer to publish the results for ethical reasons. Along with delaying publication for as long as possible "it will be more important how WE write up the study," Rowbotham wrote. "We are not allowing him to write it up himself."
More at The Globe
Pfizer tried to suppress medical studies that reached unfavorable conclusions about the effectiveness of the company's epilepsy drug Neurontin, internal Pfizer documents submitted in a lawsuit against the company showed.
The documents suggest that Pfizer's marketers influenced Neurontin's scientific record to boost sales at least until 2003 by delaying the publication or altering the conclusions of studies that had found no evidence the drug worked for various conditions besides epilepsy.
The documents, including reports by experts who reviewed thousands of company documents for plaintiffs, were submitted to the U.S. District Court in Boston.
In the case of the European study, called 224, the full findings were never published as a stand-alone paper; data from the study were pooled into results from several other Pfizer studies and published in a minor journal in 2003.
"We must delay publication of 224, as its results were not positive," wrote Pfizer marketing executive John Marino in a September 2000 e-mail to Angela Crespo, senior manager of major markets for Neurontin.
Later that month, Michael Rowbotham, Neurontin team leader, e-mailed Crespo about the problem of Dr. John Reckless, an investigator on the study who was pressing Pfizer to publish the results for ethical reasons. Along with delaying publication for as long as possible "it will be more important how WE write up the study," Rowbotham wrote. "We are not allowing him to write it up himself."
More at The Globe
Monday, April 28, 2008
Subscribe to:
Posts (Atom)